PRINCETON, N.J., July  24, 2026  (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) (ANI or the Company) today announced that the Company will release its second quarter 2026 financial results on Friday, August

ANIP

ANI Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 7, 2026 at 8:00 a.m. ET

ANI to announce Q2 2026 results on Aug 7 with webcast

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>PRINCETON, N.J., July  24, 2026  (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) (ANI or the Company) today announced that the Company will release its second quarter 2026 financial results on Friday, August</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>ANI Pharmaceuticals will release its Q2 2026 results on Aug 7, 2026 at 8:00 a.m. ET, with a live webcast hosted by CEO Nikhil Lalwani, CFO Stephen Carey, and Head of Rare Disease Chris Mutz. The event could trigger near-term moves depending on results and commentary on Rare Disease, Generics, and Brands segments.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>ANI to report Q2 2026 results on Aug 7, 2026 at 8:00 ET.</li><li>CEO Nikhil Lalwani, CFO Stephen Carey, and Chris Mut z to host call.</li><li>Webcast and replay available via ANI site; replay for up to one year.</li><li>ANI highlights Rare Disease, Generics, and Brands as key growth pillars.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>ANI Pharmaceuticals, Inc. (ANIP)</strong>: Primary subject; earnings date and webcast could drive near-term price action.</li></ul>
  </section>

  <section data-block="category">
    <h3>Earnings</h3>
    <p>Category: Earnings; fits as ANI discloses timing for Q2 results and related investor events, a key driver for near-term volatility and sentiment.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Earnings date confirmation may cause near-term volatility in ANIP.</li><li>Management commentary on Rare Disease and Generics could influence sentiment.</li><li>No pre-announced results; moves depend on the actual outcomes and guidance.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Q2 2026 results release: Aug 7, 2026, at 8:00 a.m. ET.</li><li>Hosts: Nikhil Lalwani (CEO), Stephen Carey (CFO), Chris Mutz (Head of Rare Disease).</li><li>Replay available for up to one year after the event.</li><li>ANI operates in Rare Disease, Generics, and Brands segments.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Neutral stance into Aug 7; a beat or guidance could spark a short-term rally.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p>PRINCETON, N.J., July  24, 2026  (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/ANIP">ANIP</a>) (ANI or the Company) today announced that the Company will release its second quarter 2026 financial results on Friday, August 7, 2026, at 8:00 a.m. ET.</p>  <p>Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease will host a webcast and conference call to discuss the results.</p>  <p>To view the webcast, please click <a href="https://www.globenewswire.com/Tracker?data=3xOBDl5VgAiHBKXeRodLkYS51B19ubBH54nDa4O_u_Z9VQyTkV_0bmKTJpVCA5evW5PLp1wuh-BDmbjuiykQs8L8DDC8dhJaDqi0fr589Hw=" rel="nofollow" target="_blank">here</a>. Links to access the webcast and conference call will also be available on the "Events &amp; Presentations" page of the Company’s website at <a href="https://www.globenewswire.com/Tracker?data=ZoSq3nBLYTgMBXhJlXcfI9QSEYhrxkiT64dauRvhr9VUBQ8T63H7EkL6AQAvcHcCpxVLQZaWwcG4_lsmCKd60V-vsE7uWCuFqLGVcCRuB2scOHQnjs3HCfDMuScnlmdf-t4broWfjOjVACxHOzvYAERtIcsGOEoCvIGX4skv7dkx55YYTFl10CcnPGS65je1M8TTCtVsElxypdumhazFKlQD71kEClzbxal7ZVeiXiR_X9OamIXUCxagjHVA-nE3h3-X1kZLoYo9SY4TUEu9floJbM1_uQEIcsyZGbHx8OzSp6mP4241UTrZyXmvsryi" rel="nofollow" target="_blank">https://www.anipharmaceuticals.com</a>, under the "Investors" section. A replay of the event will remain accessible for up to one year.</p>  <p><strong>About ANI</strong></p>  <p>ANI Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/ANIP">ANIP</a>) is a diversified biopharmaceutical company committed to its mission of "Serving Patients, Improving Lives&#34; by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&amp;D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visit <a href="https://www.globenewswire.com/Tracker?data=ZoSq3nBLYTgMBXhJlXcfI9QSEYhrxkiT64dauRvhr9Xm5hxCRcCnjOG0c203_i0ABgol5i8TXChN3_KXUiSGlBOd6mywODWFmWayRvST3Tf3rDvRS4ak52LjbdwUajndwnhv08wnNOoFjG_Qjbryqg==" rel="nofollow" target="_blank">https://www.anipharmaceuticals.com.</a></p>  <p><strong>Investor Relations:</strong> <br></br>Irina Koffler, Vice President, Investor Relations<br></br>T: 917-734-7387<br></br>E: Irina.koffler@anipharmaceuticals.com</p>  <p><strong>Media Relations:</strong><br></br>Argot Partners<br></br>T: 212-600-1494<br></br>E: ani@argotpartners.com</p>  <p><em>SOURCE: ANI Pharmaceuticals, Inc.</em></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTc2NjM5MSM3NzE4MTk2IzIwMTkyNjA="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/M2Y3MGI5MDYtOTE4Yi00MWRmLTk5NzktZGQ5NGQ1Yzc2ODYyLTEwMzA4MzMtMjAyNi0wNy0yNC1lbg==/tiny/ANI-Pharmaceuticals-Inc-.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/24d1d851-9075-4d6e-b22c-0c23a5ef0b36"><img src="https://ml.globenewswire.com/media/24d1d851-9075-4d6e-b22c-0c23a5ef0b36/small/ani-logo-png.png" border="0" width="150" height="63" alt="Primary Logo"></img></a></p>

ANI Pharmaceuticals will release its Q2 2026 results on Aug 7, 2026 at 8:00 a.m. ET, with a live webcast hosted by CEO Nikhil Lalwani, CFO Stephen Carey, and Head of Rare Disease Chris Mutz. The event could trigger near-term moves depending on results and commentary on Rare Disease, Generics, and Brands segments.

News insight

ANI Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 7, 2026 at 8:00 a.m. ET

AI summary

Sentiment rationale

Key facts

Earnings